Catching HIV 'in the act' with 3D electron microscopy

Trends in Microbiology

Volumn 21, Issue 8, 2013, Pages 397-404

  Earl, Lesley A ^a   Lifson, Jeffrey D ^b   Subramaniam, Sriram ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Cryo electron tomography; Focused ion beam scanning electron microscopy (FIB SEM); Ion abrasion scanning electron microscopy (IA SEM); Vaccine design; Virus cell interaction

Indexed keywords

CD209 ANTIGEN; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ANTIVIRAL ACTIVITY; BINDING SITE; CD4+ T LYMPHOCYTE; DENDRITIC CELL; DRUG DESIGN; ELECTRON MICROSCOPY; ELECTRON TOMOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; THREE DIMENSIONAL IMAGING; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS MORPHOLOGY; VIRUS TRANSMISSION;

CRYO-ELECTRON TOMOGRAPHY; FOCUSED ION BEAM SCANNING ELECTRON MICROSCOPY (FIB-SEM); ION ABRASION SCANNING ELECTRON MICROSCOPY (IA-SEM); VACCINE DESIGN; VIRUS-CELL INTERACTION;

AIDS VACCINES; DRUG DISCOVERY; HIV; IMAGING, THREE-DIMENSIONAL; MICROSCOPY, ELECTRON; MODELS, BIOLOGICAL; VIRUS INTERNALIZATION;

EID: 84881028558     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2013.06.004     Document Type: Review

References (72)

1. Liu J., et al. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109-113.
2. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
3. Dalgleish A.G., et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312:763-767.
4. Piguet V., Steinman R.M. The interaction of HIV with dendritic cells: outcomes and pathways. Trends Immunol. 2007, 28:503-510.
5. Nabel G.J., et al. Progress in the rational design of an AIDS vaccine. Philos. Trans. R. Soc. B 2011, 366:2759-2765.
6. Burton D.R., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
7. Muster T., et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993, 67:6642-6647.
8. Trkola A., et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 1995, 69:6609-6617.
9. Dhillon A.K., et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 2007, 81:6548-6562.
10. Li Y., et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 2007, 13:1032-1034.
11. Sather D.N., et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 2009, 83:757-769.
12. Doria-Rose N.A., et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 2009, 83:188-199.
13. Stamatatos L., et al. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat. Med. 2009, 15:866-870.
14. Simek M.D., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 2009, 83:7337-7348.
15. Scheid J.F., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458:636-640.
16. Scheid J.F., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333:1633-1637.
17. Kwong P.D., Mascola J.R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012, 37:412-425.
18. Zhou T., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817.
19. McLellan J.S., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
20. Huang J., et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012, 491:406-412.
21. Pejchal R., et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11483-11488.
22. Merk A., Subramaniam S. HIV-1 envelope glycoprotein structure. Curr. Opin. Struct. Biol. 2013, 23:268-276.
23. White T.A., et al. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog. 2010, 6:e1001249.
24. Harris A., et al. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:11440-11445.
25. Meyerson J.R., et al. Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:513-518.
26. Frank G.A., et al. Computational separation of conformational heterogeneity using cryo-electron tomography and 3D sub-volume averaging. J. Struct. Biol. 2012, 178:165-176.
27. Zhu P., et al. Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs. PLoS Pathog. 2008, 4:e1000203.
28. Wu X., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
29. Corti D., et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 2010, 5:e8805.
30. Walker L.M., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
31. Walker L.M., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
32. Bonsignori M., et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 2011, 85:9998-10009.
33. Tran E.E., et al. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog. 2012, 8:e1002797.
34. Ofek G., et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 2004, 78:10724-10737.
35. Cardoso R.M., et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005, 22:163-173.
36. Pejchal R., et al. A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J. Virol. 2009, 83:8451-8462.
37. Weissenhorn W., et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387:426-430.
38. Buzon V., et al. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 2010, 6:e1000880.
39. Harris A.K., et al. HIV-1 envelope glycoprotein trimers display open quaternary conformation when bound to the gp41 membrane-proximal external-region-directed broadly neutralizing antibody Z13e1. J. Virol. 2013, 87:7191-7196.
40. Shibata R., et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 1999, 5:204-210.
41. Mascola J.R., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000, 6:207-210.
42. Hessell A.J., et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009, 5:e1000433.
43. Chen B.K. T cell virological synapses and HIV-1 pathogenesis. Immunol. Res. 2012, 54:133-139.
44. Sharova N., et al. Macrophages archive HIV-1 virions for dissemination in trans. EMBO J. 2005, 24:2481-2489.
45. Carr J.M., et al. Rapid and efficient cell-to-cell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. Virology 1999, 265:319-329.
46. Cameron P.U., et al. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science 1992, 257:383-387.
47. Nath A., et al. Infection of human fetal astrocytes with HIV-1: viral tropism and the role of cell to cell contact in viral transmission. J. Neuropathol. Exp. Neurol. 1995, 54:320-330.
48. Piguet V., Sattentau Q. Dangerous liaisons at the virological synapse. J. Clin. Invest. 2004, 114:605-610.
49. Bennett A.E., et al. Ion-abrasion scanning electron microscopy reveals surface-connected tubular conduits in HIV-infected macrophages. PLoS Pathog. 2009, 5:e1000591.
50. Mothes W., et al. Virus cell-to-cell transmission. J. Virol. 2010, 84:8360-8368.
51. Chen P., et al. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J. Virol. 2007, 81:12582-12595.
52. Dimitrov D.S., et al. Quantitation of human immunodeficiency virus type 1 infection kinetics. J. Virol. 1993, 67:2182-2190.
53. Aquaro S., et al. Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J. Med. Virol. 2002, 68:479-488.
54. Brown A., et al. In vitro modeling of the HIV-macrophage reservoir. J. Leukoc. Biol. 2006, 80:1127-1135.
55. Lekkerkerker A.N., et al. Viral piracy: HIV-1 targets dendritic cells for transmission. Curr. HIV Res. 2006, 4:169-176.
56. Wang J.H., et al. Functionally distinct transmission of human immunodeficiency virus type 1 mediated by immature and mature dendritic cells. J. Virol. 2007, 81:8933-8943.
57. Arrighi J.F., et al. DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. J. Exp. Med. 2004, 200:1279-1288.
58. Gringhuis S.I., et al. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat. Immunol. 2010, 11:419-426.
59. Vasiliver-Shamis G., et al. HIV-1 virological synapse is not simply a copycat of the immunological synapse. Viruses 2010, 2:1239-1260.
60. McDonald D., et al. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003, 300:1295-1297.
61. Felts R.L., et al. 3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13336-13341.
62. Nikolic D.S., et al. HIV-1 activates Cdc42 and induces membrane extensions in immature dendritic cells to facilitate cell-to-cell virus propagation. Blood 2011, 118:4841-4852.
63. Zhong P., et al. Cell-to-cell transmission of viruses. Curr. Opin. Virol. 2013, 3:44-50.
64. Blumenthal R., et al. HIV entry and envelope glycoprotein-mediated fusion. J. Biol. Chem. 2012, 287:40841-40849.
65. Sougrat R., et al. Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog. 2007, 3:e63.
66. Dobrowsky T.M., et al. Organization of cellular receptors into a nanoscale junction during HIV-1 adhesion. PLoS Comput. Biol. 2010, 6:e1000855.
67. Lifson J.D., Haigwood N.L. Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones. Cold Spring Harb. Perspect. Med. 2012, 2:a007310.
68. Flynn N.M., et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 2005, 191:654-665.
69. Pitisuttithum P., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 2006, 194:1661-1671.
70. Rerks-Ngarm S., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220.
71. O'Connell R.J., et al. Human immunodeficiency virus vaccine trials. Cold Spring Harb. Perspect. Med. 2012, 2:a007351.
72. Karasavvas N., et al. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res. Hum. Retroviruses 2012, 28:1444-1457.